117 related articles for article (PubMed ID: 23007009)
1. Epidermal growth factor receptor: a re-emerging target in glioblastoma.
Hegi ME; Rajakannu P; Weller M
Curr Opin Neurol; 2012 Dec; 25(6):774-9. PubMed ID: 23007009
[TBL] [Abstract][Full Text] [Related]
2. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
Ezzati S; Salib S; Balasubramaniam M; Aboud O
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993
[TBL] [Abstract][Full Text] [Related]
3. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?
Ge M; Zhu Y; Wei M; Piao H; He M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188996. PubMed ID: 37805108
[TBL] [Abstract][Full Text] [Related]
4. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.
De Witt Hamer PC
Neuro Oncol; 2010 Mar; 12(3):304-16. PubMed ID: 20167819
[TBL] [Abstract][Full Text] [Related]
5. A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinase.
Giglio RM; Hou N; Wyatt A; Hong J; Shi L; Vaikunthan M; Fuchs H; Nima JP; Malinowski SW; Ligon KL; McFaline-Figueroa JR; Yosef N; Azizi E; McFaline-Figueroa JL
bioRxiv; 2024 Apr; ():. PubMed ID: 38645018
[TBL] [Abstract][Full Text] [Related]
6. Targeting androgen receptor in glioblastoma.
Gan X; Liu Y; Wang X
Crit Rev Oncol Hematol; 2023 Nov; 191():104142. PubMed ID: 37742885
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
8. Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma.
Padfield E; Ellis HP; Kurian KM
Front Oncol; 2015; 5():5. PubMed ID: 25688333
[TBL] [Abstract][Full Text] [Related]
9. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
[TBL] [Abstract][Full Text] [Related]
11. The somatic genomic landscape of glioblastoma.
Brennan CW; Verhaak RG; McKenna A; Campos B; Noushmehr H; Salama SR; Zheng S; Chakravarty D; Sanborn JZ; Berman SH; Beroukhim R; Bernard B; Wu CJ; Genovese G; Shmulevich I; Barnholtz-Sloan J; Zou L; Vegesna R; Shukla SA; Ciriello G; Yung WK; Zhang W; Sougnez C; Mikkelsen T; Aldape K; Bigner DD; Van Meir EG; Prados M; Sloan A; Black KL; Eschbacher J; Finocchiaro G; Friedman W; Andrews DW; Guha A; Iacocca M; O'Neill BP; Foltz G; Myers J; Weisenberger DJ; Penny R; Kucherlapati R; Perou CM; Hayes DN; Gibbs R; Marra M; Mills GB; Lander E; Spellman P; Wilson R; Sander C; Weinstein J; Meyerson M; Gabriel S; Laird PW; Haussler D; Getz G; Chin L;
Cell; 2013 Oct; 155(2):462-77. PubMed ID: 24120142
[TBL] [Abstract][Full Text] [Related]
12. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.
Gan HK; Cvrljevic AN; Johns TG
FEBS J; 2013 Nov; 280(21):5350-70. PubMed ID: 23777544
[TBL] [Abstract][Full Text] [Related]
13. Profile of nimotuzumab in the treatment of high-grade glioma.
Yang QY; Guo CC; Chen ZP
Onco Targets Ther; 2015; 8():819-25. PubMed ID: 25926743
[TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
Lau D; Magill ST; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
[TBL] [Abstract][Full Text] [Related]
15. EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.
Zahonero C; Sánchez-Gómez P
Cell Mol Life Sci; 2014 Sep; 71(18):3465-88. PubMed ID: 24671641
[TBL] [Abstract][Full Text] [Related]
16. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.
Sottoriva A; Spiteri I; Piccirillo SG; Touloumis A; Collins VP; Marioni JC; Curtis C; Watts C; Tavaré S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4009-14. PubMed ID: 23412337
[TBL] [Abstract][Full Text] [Related]
17. Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm.
Wang L; Wang H; D'Angelo F; Curtin L; Sereduk CP; Leon G; Singleton KW; Urcuyo J; Hawkins-Daarud A; Jackson PR; Krishna C; Zimmerman RS; Patra DP; Bendok BR; Smith KA; Nakaji P; Donev K; Baxter LC; Mrugała MM; Ceccarelli M; Iavarone A; Swanson KR; Tran NL; Hu LS; Li J
PLoS One; 2024; 19(4):e0299267. PubMed ID: 38568950
[TBL] [Abstract][Full Text] [Related]
18. Image-localized biopsy mapping of brain tumor heterogeneity: A single-center study protocol.
Urcuyo JC; Curtin L; Langworthy JM; De Leon G; Anderies B; Singleton KW; Hawkins-Daarud A; Jackson PR; Bond KM; Ranjbar S; Lassiter-Morris Y; Clark-Swanson KR; Paulson LE; Sereduk C; Mrugala MM; Porter AB; Baxter L; Salomao M; Donev K; Hudson M; Meyer J; Zeeshan Q; Sattur M; Patra DP; Jones BA; Rahme RJ; Neal MT; Patel N; Kouloumberis P; Turkmani AH; Lyons M; Krishna C; Zimmerman RS; Bendok BR; Tran NL; Hu LS; Swanson KR
PLoS One; 2023; 18(12):e0287767. PubMed ID: 38117803
[TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma.
Cao W; Xiong L; Meng L; Li Z; Hu Z; Lei H; Wu J; Song T; Liu C; Wei R; Shen L; Hong J
Heliyon; 2023 Jul; 9(7):e18310. PubMed ID: 37519736
[TBL] [Abstract][Full Text] [Related]
20. Tumor Microenvironment and Glioblastoma Cell Interplay as Promoters of Therapeutic Resistance.
Agosti E; Panciani PP; Zeppieri M; De Maria L; Pasqualetti F; Tel A; Zanin L; Fontanella MM; Ius T
Biology (Basel); 2023 May; 12(5):. PubMed ID: 37237548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
